Navigation Links
Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 6, 2007 - CombinatoRx, Incorporated (NASDAQ: CRXX), today announced that data from its randomized, blinded, placebo-controlled phase 2 clinical trials of CRx-102 in patients with osteoarthritis (OA) and rheumatoid arthritis (RA) will be featured at the European League against Rheumatism (EULAR) Annual Congress of Rheumatology meeting, June 13-16, 2007 in Barcelona, Spain.

Schedule of Events:

-- Satellite Symposium, Room 111, Thursday, June 14, 2007 8:15-9:45am

"Novel Approaches to Improve Treatment Outcomes in Arthritis"

Co-Chairs: Steven Abramson, MD, Professor, Medicine and Pathology, Hospital for Joint Diseases, New York, NY and Josef Smolen, MD, Professor, Rheumatology, Medical University of Vienna, Vienna, Austria.

-- Poster #THU0051, Thursday, June 14, 2007, 11:45-1:30pm

"Inhibition of Macrophage and Chrondrocyte Inflammatory Mediators by CRx-102, a Novel Synergistic Combination Drug Candidate", Fraser, et.al.

-- Poster #SAT0236, Saturday, June 16, 2007, 10:15-11:45am

"Response and State-Attainment Criteria in Hand OA: Analyses from a Placebo-Controlled Clinical Trial of CRx-102, a Novel Synergistic Combination Therapy", Kvien, et.al.

-- Poster #SAT0049, Saturday, June 16, 2007, 10:15-11:45am

"A Phase 2a Trial to Evaluate CRx-102 for the Treatment of Active Rheumatoid Arthritis", Kirwan, et.al.

Abstracts are currently available online via the EULAR website (www.EULAR.org) and the posters will be available on the CombinatoRx website (www.combinatorx.com) following presentation.

About CRx-102

CRx-102 is an oral synergistic combination drug candidate containing the cardiovascular agent dipyridamole and an unconventionally low dose of the steroid prednisolone. CRx-102 works through a novel mechanism of action in which dipyridamole selectively amplifies prednisolone's anti-inflammatory and
'"/>




Page: 1 2 3

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
7. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
8. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
9. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
10. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
11. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
Post Your Comments:
(Date:7/11/2014)... , July 11, 2014  Veran ... company, announced today the positive, cost-effective final ... innovative SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous ... a percutaneous approach to biopsy when a ... patients and physicians experience positive financial outcomes ...
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the largest ... MiE America , Inc., a leading provider of Siemens ... a long-term agreement naming BC Technical as the authorized ... MiE and BC Technical announced today that ... establish BC Technical as the service and systems provider ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... will evaluate R7128 1000mg BID in HCV genotype 1, ... 2 or 3 ... treatment-experienced patients -, PRINCETON, N.J., May 14 ... additional cohorts of a 4-week,Phase 1 study of R7128 in ...
... (Nasdaq: KOSN ) today announced that updated data ... from a Phase,2 trial in combination with Herceptin(R) in ... Meeting of the American,Society of Clinical Oncology (ASCO), being ... 3, 2008., Abstract 1027, titled, "Phase 2 trial ...
Cached Medicine Technology:Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C 2Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C 3Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C 4Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 2Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 3
(Date:7/13/2014)... July 13, 2014 Micro irrigation systems ... proper water dispersal as wells as to maintain soil ... is projected to become a dominant revenue generator for ... methods to reduce resource costs has led to the ... plantations, and has further caused massive demand for micro ...
(Date:7/13/2014)... additives are chemicals, which are added to various fuels ... on, in order to enhance their performance. Fuel additives ... by fuels and improving the combustion properties of fuels. ... scale in the long run, but, in the short ... products. , The various fuel additive types include deposit ...
(Date:7/13/2014)... 2014 A Massachusetts couple who have ... risks associated with power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) ... federal regulators, as they presented poignant testimony on the ... Administration (FDA) advisory panel meeting convened to address the ... Rochester Democrat and Chronicle, Dr. Hooman Noorchashm and his ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Max ... Famer, Chris Mullin, will be the featured guest at ... 26th in Puerto Rico. Attendees will learn about ... participate in two exhibition basketball games and perform in ... supplier of health- and energy-boosting supplements , has ...
Breaking Medicine News(10 mins):Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 2Health News:Agricultural Micro Irrigation System Market is Expected to Grow at a CAGR of 18.1%, from 2013 to 2018 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 2Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 3Health News:Couple Who Brought Attention to Morcellator Cancer Risks Testify on Second Day of FDA Advisory Panel Meeting, Bernstein Liebhard LLP Reports 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4
... By Jenifer Goodwin HealthDay Reporter , THURSDAY, ... antigen (PSA) levels are rising rapidly over time are of ... be done, a new study indicates. PSA is a ... of PSA can be a marker for prostate cancer, although ...
... By Amanda Gardner HealthDay Reporter , THURSDAY, Feb. ... plague will probably remain a scourge of centuries past, isolated ... fact, according to a just-released government report, a American lab ... of plague from a laboratory-acquired infection since 1959 and the ...
... , THURSDAY, Feb. 24 (HealthDay News) -- ... risk of cancer due to high radiation doses, and ... radiation exposure, a new study suggests. The researchers ... dialysis also have other health conditions that require them ...
... cancer organizations have recommended that men with a rapid rise ... there is no other indication and the PSA is within ... PSA velocityis a poor predictor of prostate cancer, and may ... online February 24 in the Journal of the National ...
... link between victimization experiences and substance abuse has been ... Chicago. The correlation is especially prevalent among gays, ... says Tonda Hughes, professor and interim head of health ... is lead author of the study, published in the ...
... THURSDAY, Feb. 24 (HealthDay News) -- A mouse heart rapidly ... a day after birth, scientists report. With this discovery, ... be found to help the human heart heal itself. ... but they,re somehow permanently switched off," said Eric Olson, co-senior ...
Cached Medicine News:Health News:Rapid Rise in PSA Levels a Poor Predictor of Prostate Cancer: Study 2Health News:Rapid Rise in PSA Levels a Poor Predictor of Prostate Cancer: Study 3Health News:Plague Kills U.S. Lab Worker 2Health News:Plague Kills U.S. Lab Worker 3Health News:Many Dialysis Patients at Risk for High Radiation Exposure 2Health News:PSA velocity screening for prostate cancer may lead to unnecessary biopsies 2Health News:Strong link found between victimization, substance abuse 2Health News:Scientists Say Newborn Mice Can Regrow Damaged Hearts 2
Cold light source triple outlet....
Cold light source dual outlet....
Cold light source triple outlet....
With the LX300, you don't have to compromise the quality of your lighting system to meet your budget needs. You get the best and whitest light possible from an affordable 300 Watt light source....
Medicine Products: